← Back to Search

Checkpoint Inhibitor

Lamivudine + Chemoimmunotherapy for Small Cell Lung Cancer

Phase 2
Recruiting
Led By Grace K Dy
Research Sponsored by Roswell Park Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Received no more than one-line of treatment with platinum-based chemotherapy for SCLC, and
Histologically or cytologically confirmed diagnosis of small cell lung cancer (SCLC)
Must not have
Positive for immunosuppressive disease, acquired immunodeficiency syndrome (AIDS) or other immune depressing diseases. For human immunodeficiency virus (HIV), HVC and HBC-mandatory testing is required prior to enrollment
Active, clinically serious infections or other serious uncontrolled medical conditions, including chronic viral hepatitis (testing for hepatitis B, C required)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from registration to death from any cause or 5 years from time of enrollment, whichever occurs first
Awards & highlights

Summary

This trial studies if adding lamivudine to standard treatment can help patients with advanced small cell lung cancer. Lamivudine may prevent cancer cells from becoming resistant, while the standard treatment kills the cells and boosts the immune system.

Who is the study for?
Adults with extensive stage small cell lung cancer who have measurable disease, acceptable organ function, and an ECOG performance status of 0 or 1. They may have had one cycle of chemoimmunotherapy but no more than one prior line of platinum-based treatment at least a year ago without progression during that treatment. Participants must not be HIV positive or have certain other health conditions.
What is being tested?
The trial is testing the effectiveness of adding lamivudine to standard chemoimmunotherapy (carboplatin, etoposide, and atezolizumab) for treating extensive stage small cell lung cancer. The goal is to see if lamivudine can help prevent the tumor from becoming resistant to therapy.
What are the potential side effects?
Possible side effects include reactions related to immune system activation such as inflammation in various organs, fatigue, digestive issues like nausea and diarrhea, blood-related problems including low counts leading to increased infection risk, liver enzyme changes, and potential allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had only one round of platinum-based chemotherapy for small cell lung cancer.
Select...
My lung cancer diagnosis was confirmed through lab tests.
Select...
My cancer has spread beyond my lungs.
Select...
I have small cell lung cancer and have had only one round of chemotherapy or chemoimmunotherapy.
Select...
I can carry out all my self-care but cannot work.
Select...
I am 18 years old or older.
Select...
My kidney function tests are within normal range.
Select...
My cancer can be measured and tracked using specific criteria.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a condition that weakens my immune system, such as HIV/AIDS.
Select...
I do not have any serious infections or uncontrolled conditions, including hepatitis.
Select...
My cancer has spread to the lining of my brain and spinal cord.
Select...
I have irregular heartbeats that are not well-managed.
Select...
I have brain metastasis causing symptoms.
Select...
I haven't had major surgery or still recovering from one in the last 2 weeks.
Select...
I haven't had chemotherapy or chemoimmunotherapy in the last 4 weeks, except for allowed treatments.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from registration to death from any cause or 5 years from time of enrollment, whichever occurs first
This trial's timeline: 3 weeks for screening, Varies for treatment, and from registration to death from any cause or 5 years from time of enrollment, whichever occurs first for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Progression-free survival
Secondary study objectives
Incidence of toxicities
Overall survival

Side effects data

From 2015 Phase 3 trial • 3526 Patients • NCT00074581
8%
Blood bilirubin increased
8%
Blood phosphorus decreased
8%
Abnormal loss of weight
7%
Neutropenia
7%
Neutrophil count decreased
5%
Hypophosphataemia
4%
Aspartate aminotransferase increased
4%
Hyperbilirubinaemia
3%
Malaria
2%
Alanine aminotransferase increased
2%
Anaemia
2%
Pneumonia
2%
Haemoglobin decreased
2%
Dizziness
1%
Blood albumin decreased
1%
Hypertension
1%
Diarrhoea
1%
Blood sodium decreased
1%
Dyslipidaemia
1%
Abortion spontaneous
1%
Completed suicide
1%
Suicidal ideation
1%
Thrombocytopenia
1%
Deep vein thrombosis
1%
Diarrhoea haemorrhagic
1%
Gastroenteritis
1%
Pelvic inflammatory disease
1%
Pneumonia bacterial
1%
Platelet count decreased
1%
Transaminases increased
1%
Abortion incomplete
1%
Death
1%
Hepatotoxicity
1%
Urinary tract infection
1%
Suicide attempt
100%
80%
60%
40%
20%
0%
Study treatment Arm
Early-ART
Delayed-ART

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (lamivudine, chemoimmunotherapy)Experimental Treatment4 Interventions
INDUCTION: Patients receive lamivudine PO QD on days 1-28. Patients also receive carboplatin IV over 30-60 minutes and atezolizumab IV on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive lamivudine PO QD on days 1-28 and atezolizumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. NOTE: Patients who are not eligible for atezolizumab as outlined in exclusion criteria or who refuse to receive atezolizumab may still be treated in this study with carboplatin and etoposide as the IV drug component, in addition to lamivudine orally administered.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Etoposide
2010
Completed Phase 3
~2960
Lamivudine
2006
Completed Phase 4
~8120
Atezolizumab
2017
Completed Phase 3
~5850
Carboplatin
2014
Completed Phase 3
~6120

Find a Location

Who is running the clinical trial?

Roswell Park Cancer InstituteLead Sponsor
408 Previous Clinical Trials
32,390 Total Patients Enrolled
Grace K DyPrincipal InvestigatorRoswell Park Cancer Institute
2 Previous Clinical Trials
17 Total Patients Enrolled

Media Library

Atezolizumab (Checkpoint Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04696575 — Phase 2
Small Cell Lung Cancer Research Study Groups: Treatment (lamivudine, chemoimmunotherapy)
Small Cell Lung Cancer Clinical Trial 2023: Atezolizumab Highlights & Side Effects. Trial Name: NCT04696575 — Phase 2
Atezolizumab (Checkpoint Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04696575 — Phase 2
~5 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top